Skip to main content
. 2020 Apr 24;15(4):e0232365. doi: 10.1371/journal.pone.0232365

Fig 6. Monitoring of BRAF-mutated ctDNA concentrations according to treatment response.

Fig 6

Mutated BRAF ctDNA levels at various time points in six patients. The vertical axis represents mutated BRAF ctDNA concentration, and the horizontal axis represents the time points of plasma-sampling days. All patients were administrated oral cyclooxygenase-2 inhibitors during treatment. CR, complete response; SD, stable disease; PD, progressive disease; PR, partial response; MIT, mitoxantrone; CBDCA, carboplatin; LPAM, Melphalan.